Last reviewed 2026-04-23 · How we verify

609A

609A is a small molecule drug that targets the molecular target.

609A is a small molecule drug that targets the molecular target. Used for Unknown indication.

At a glance

Mechanism of action

The exact mechanism of action of 609A is not well understood, but it is believed to work by binding to the molecular target, which results in the desired therapeutic effect.

Approved indications

• Unknown indication

Common side effects

• Unknown adverse event

Key clinical trials

• Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (PHASE1)
• A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma (PHASE2)
• A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma (PHASE2)
• Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China (NA)
• Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.